SSStefan Seregard

Stefan Seregard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stefan Seregard has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Drusen maculopathy: a risk factor for visual deterioration

    by Peep V. Algvere, Anders Kvanta, Stefan Seregard

    Age‐related macular degeneration (AMD), the most common cause of visual loss after the age of 65, displays a degeneration of the retinal pigment epithelial (RPE) cells and photoreceptors in the retinal centre (macula). The central macula (fovea) that contains mostly cone photoreceptors mediates the high visual acuity. Drusen maculopathy may lead to visual deterioration. Drusen are extracellular deposits of debris that accumulate on Bruch′s membrane. Drusen attract inflammatory, immunological and vasoactive stimuli. RPE and photoreceptor cells overlying drusen exhibit biochemical and morphological signs of degeneration. Strong and intermittent light exposure (photons) induces the formation of free radicals in the very high oxygen tension milieu of the retina. The negative effects of irradiation stimulate accumulation of lipofuscin in RPE and photoreceptor cells leading to mitochondrial dysfunction and apoptotic cell death. A hydrophobic barrier is built up in Bruch′s membrane reducing diffusion to the choroid. Hereditary and inflammatory factors modify the risk for AMD. There is a genetic dysregulation of the complement system leading to inappropriate complement activation. The genetic polymorphism of complement factor H (CFH) and age‐related maculopathy susceptibilty 2 (ARMS2) increase the risk of progression to advanced AMD. The photoelectric effect creates free radicals, resulting in a continuous increase of lipofuscin formation and impairing mitochondrial activity. In addition, inflammation and complement dysregulation contribute to the formation of drusen and vasoproliferative reactions with neovascularization. Antioxidants neutralize reactive oxygen species and reduce lipofuscin accumulation in RPE and photoreceptor cells. For prophylactic treatment of drusen maculopathy, high doses of antioxidants such as vitamins C and E, lutein, zeaxanthine and zinc are used according to the Age‐Related Eye Disease Study 2 (AREDS 2). The risk of developing advanced AMD was reduced by 27% at 10 years follow‐up. No adverse events were noted.


  • Conjunctiva

    by Stefan Seregard, Maria Antonietta Blasi, Emilio Balestrazzi


  • Cancer Pathology

    by Katarina Bartuma, Charlotta All-Ericsson, Stefan Seregard

  • Radiation Therapy: Uveal Tumors

    by Stefan Seregard, David E. Pelayes, Arun D. Singh

    Among primary uveal tumors, uveal melanoma is the most frequently occurring malignant neoplasm, albeit much less common than skin melanoma and indeed most other cancers. Traditionally, uveal melanoma was treated by enucleation of the globe, but is now increasingly been managed by an eye-preserving option, which saves vision without compromising the life of patients. More than 90% of eyes now preserved have some form of radiotherapy; most often episcleral brachytherapy that is easily accessible at many ophthalmic centers. Conversely, teletherapy in the form of charged particle irradiation, stereotactic radiotherapy or radiosurgery is only available at a comparatively small number of centers. Radiotherapy for uveal melanoma causes significant side effects and complications, but the vast majority of patients can keep their eye with some remaining function. This is of significant benefit to the quality of life for many patients. The side effects of radiotherapy are intimately related to the size of the irradiated tumor, hence early detection and identification of tumors that need to be treated is critical to improve the functional outcome. Experience gained from treating uveal melanoma has been expanded to treat benign uveal tumors such as choroidal hemangioma and other malignant tumors such as uveal lymphoma and uveal metastasis.


  • Diagnostic incisional biopsies in clinically indeterminate choroidal tumours

    by S Seregard, C All-Ericsson, L Hjelmqvist, L Berglin, A Kvanta

    Most intraocular tumours are reliably diagnosed by a careful clinical examination combined with one or more non-invasive diagnostic techniques. However, in a small percentage of tumours, typically small and clinically amelanotic, the features are insufficiently distinct for a confident clinical diagnosis and tissue is required for diagnosis. We used a 23-G vitreous cutter to access the biopsy site in 43 patients with clinically indeterminate tumours. After retinotomy, an incisional choroidal biopsy yielded a specimen of ~1 mm3. Obtained tissue was routinely processed for light microscopy including an immunohistochemical panel of monoclonal antibodies. Adequate tissue for diagnosis was provided in 41/43 (95%) patients. The sensitivity and specificity to detect malignant disease were 0.97 and 1.00, respectively. The positive predictive value was 1.00. Complications included progression of pre-existing retinal detachment in 5/43 (12%) patients and transient rise in intraocular pressure to >40 mm Hg in 6/43 (14%) patients; 4 of these 6 patients had a pre-existing retinal detachment. No patient with a pre-operatively attached retina had a retinal detachment. We conclude that an incisional transretinal choroidal biopsy yields abundant material and may adequately confirm or exclude malignancy in patients with clinically indeterminate tumours. The complication rate can be minimised when patients with pre-existing retinal detachment are excluded from biopsy.


  • Fine Needle Aspiration Cytology in Orbital Tumors

    by Stefan Seregard, Edneia Tani


    • 16 October 2009
      • Vol. 106  (35) , 2153-4

    [HSAN decision a threat against Swedish ophthalmologic care].

    by Stefan Seregard

  • Open Access

    Receptors for the liver synthesized growth factors IGF‐1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications

    by Mario A. Economou, Charlotta All‐Ericsson, Vladimir Bykov, Leonard Girnita, Armando Bartolazzi, Olle Larsson, Stefan Seregard

    Purpose:  Uveal melanoma disseminates preferentially to the liver. The mechanism for this homing is largely unknown, but growth factors synthesized in the liver may be involved. The present study was undertaken to investigate the possible relationship between cell surface receptors for two such growth factors: the c‐Met proto‐oncogene, which constitutes the receptor for hepatocyte growth factor/scatter factor (HGF/SF), and the insulin‐like growth factor 1 receptor (IGF‐1R). Their role as a prognostic factor was also clarified.Methods:  Paraffin‐embedded tumor specimens from 132 patients with primary uveal melanoma were analyzed by using well‐established specific antibodies against c‐Met and IGF‐1R. The intercorrelation of receptor expression and association with melanoma‐related survival of patients were determined by univariate and multivariate analyses.Results:  Whereas the expression of both IGF‐1R and c‐Met was significantly associated with melanoma‐specific mortality by univariate analysis (p = 0.004 and p = 0.007, respectively) only IGF‐1R showed independent prognostic value by multivariate analysis, p = 0.004. The prognostic value of IGF‐1R was stronger than such currently used prognostic parameters as tumor cell type and tumor diameter (p = 0.021 and p = 0.026, respectively). The expression patterns of the two growth factors receptors were weakly intercorrelated.Conclusions:  In conclusion, the data suggest that the receptors for IGF‐1 and HGF/SF may play a role in the spread of uveal melanoma and its affinity to the liver. The strong correlation between IGF‐1R expression and melanoma‐specific mortality points to the use of IGF‐1R as a prognostic tool [Economou MA, All‐Ericsson C, Bykov V, Girnita L, Bartolazzi A, Larsson O & Seregard S (2005): Receptors for the liver synthesized growth factors IGF‐1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications. Invest Ophthalmol Vis Sci46: 4372–4375].